Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome

by Palobiofarma

Palobiofarma S.L., una empresa biofarmacéutica dedicada al descubrimiento y desarrollo de fármacos innovadores para enfermedades huérfanas, ha anunciado hoy el logro de varios hitos importantes en ...

Read more

Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease

by Palobiofarma

Palobiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Dual Antagonist Compounds Targeting A2A and H3 Receptors for the Treatment o...

Read more

Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD.

by Palobiofarma

Primary endpoint was achieved, with PBF-680 demonstrating a statistically significant reduction in blood eosinophil count over 4 weeks. Reduction in blood eosinophil count correlated with statisticall...

Read more

Palobiofarma announces the completion the Phase II clinical trial with its investigational therapy PBF-680 in chronic obstructive pulmonary disease (COPD) patients

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients.

Read more

PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)

by Palobiofarma

The Orphan Drug Designation indicates the acknowledgement by the Regulatory Authorities of USA and the EU that PBF-999 have the potential to address the specific needs of individuals suffering from Pr...

Read more

Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team

by Palobiofarma

The investment will be used to complete three phase II clinical trials in which the efficacy of its most advanced products is being studied, namely PBF-680 in patients with chronic obstructive pulmona...

Read more

Palobiofarma Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome

by Palobiofarma

Palobiofarma has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10 (PDE-10) inhibitor, PBF-999, f...

Read more

Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome

by Palobiofarma

Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study to investigate the potential of...

Read more

Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome

by Palobiofarma

FPWR’s philanthropic investment will be used to partially fund Palobiofarma’s ongoing Phase 2 clinical trial to develop PBF-999 for the treatment of Prader Willi syndrome (PWS).

Read more

Medibiofarma cierra nueva ronda de financiación por valor de 1,

by Palobiofarma

Medibiofarma ha cerrado una ronda de financiación de 1,2 millones de euros, con el apoyo financiero de su equipo promotor y otros socios de contrastada experiencia en el ámbito de la salud y la tecn...

Read more

Palobiofarma announces that it has been included among the 99 innovative companies in the European Innovation Council Accelerator

by Palobiofarma

Palobiofarma has received the approval of the European project that finances Phase II of the PBF-680 product in COPD. Additionally, it offers the possibility of partial financing of Phase III of PBF-6...

Read more

Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis

by Palobiofarma

The Phase II trial studied the safety, tolerability, and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care Mesalazi...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Rethinking Alzheimer’s clinical trials...

by Fundació Clínic per a la Recerca Biomèdica

A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...

Photos Stream